Binding affinity and HLA/peptide complex stability of CYP1B1-derived and control peptides to human HLA-A*0201
. | . | . | . | T2 assay . | . | . | |
|---|---|---|---|---|---|---|---|
| Peptide . | Protein . | Position . | Sequence . | Maximum, FI* . | t1/2, h† . | IC50, nmol‡ . | |
| CYP190 | CYP1B1 | 190 | FLDPRPLTV | 3.7 | 10.1 | 67 | |
| CYP239 | CYP1B1 | 239 | SLVDVMPWL | 3.9 | 3.3 | 63 | |
| Controls | |||||||
| Positive | MAGE-3 | 271 | FLWGPRALV | 3.2 | 3.4 | ND | |
| Negative | Idiotype | 98 | AHTKDGFNF | 0 | ND | ND | |
. | . | . | . | T2 assay . | . | . | |
|---|---|---|---|---|---|---|---|
| Peptide . | Protein . | Position . | Sequence . | Maximum, FI* . | t1/2, h† . | IC50, nmol‡ . | |
| CYP190 | CYP1B1 | 190 | FLDPRPLTV | 3.7 | 10.1 | 67 | |
| CYP239 | CYP1B1 | 239 | SLVDVMPWL | 3.9 | 3.3 | 63 | |
| Controls | |||||||
| Positive | MAGE-3 | 271 | FLWGPRALV | 3.2 | 3.4 | ND | |
| Negative | Idiotype | 98 | AHTKDGFNF | 0 | ND | ND | |
FI indicates mean fluorescence with peptide/mean fluorescence without peptide; ND, not determined.
The known HLA-A*0201-binding peptide from MAGE-3 and a nonbinding peptide from an idiotype sequence were used as positive and negative controls. Results from 1 of 5 representative experiments are shown.
Time to half-maximal FI after withdrawal of peptide was calculated using linear regression analysis.
Peptide concentration necessary to inhibit binding of a labeled reference peptide HBV core 18-27 to HLA-A*0201 by 50%.